

Freedom of Information Request	FOI 22-438	29 th September 2022
--------------------------------	------------	---------------------------------

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Baricitinib [Olumiant]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Filgotinib [Jyseleca]**
- **Golimumab [Simponi]**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**
- **Rituximab [MabThera]**
- **Rituximab Biosimilars**
- **Sarilumab [Kevzara]**
- **Secukinumab [Cosentyx]**
- **Tocilizumab [Ro Actemra]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**

Please find below the quantities dispensed from the Health Board pharmacies for the period June 2022 – August July 2022 for rheumatology only.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Description	Quantity
ABATACEPT (ORENCIA CLICKJECT) 125 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	11
ABATACEPT (ORENCIA) 125 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	29
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	10
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	88
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	32

Description	Quantity
ADALIMUMAB (IMRALDI) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	138
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack	90
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	127
ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	195
ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	23
ETANERCEPT (ENBREL) 25 mg in 0.5mL Pre-Filled Pen 4 Pre-Filled Pen Pack	4
ETANERCEPT (ENBREL) 25 mg in 0.5mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	6
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	25
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	6
GOLIMUMAB (SIMPONI) 100 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	4
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Pen 1 Pre-Filled Pen Pack	49
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	2
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	18
INFLIXIMAB (REMICADE) 100 mg Intravenous Infusion 1 Vial Pack	15
IXEKIZUMAB (TALTZ) 80 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	23
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	64
SARILUMAB (KEVZARA) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack	16
SECUKINUMAB 150 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack	49
SECUKINUMAB 150 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	2
SECUKINUMAB 300 mg in 2mL Pre-Filled Pen 1 Pre-Filled Pen Pack	2
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Pen 4 Pre-Filled Pen Pack	46
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	52
TOCILIZUMAB 200 mg in 10mL Intravenous Infusion 1 Vial Pack	11
TOCILIZUMAB 400 mg in 20mL Intravenous Infusion 1 Vial Pack	10
TOCILIZUMAB 80 mg in 4mL Intravenous Infusion 1 Vial Pack	11

Description	Quantity
TOFACITINIB 5 mg Tablets 56 Tablet Pack	11
USTEKINUMAB 45 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	6
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4

Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Golimumab [Simponi]**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**

The Health Board unable to provide this information it is not recorded centrally. In order to determine this the Health Board would have to review every record. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.